...Thank you. Thank you, everyone, for joining us this afternoon, and sorry about the news this morning. I want to talk about 3 things as we look back on 2021. Number one, we moved Tyvaso DPI from concept to an NDA filing and passing an FDA inspection. We are fully staffed and moving into ensuring commercial product is ready upon FDA approval. Number two, we recapitalized the company early last year to put us on a sound path of success and ensure that we didn't have to make dramatic changes to our operating model or our structure and our strategy, given the types of setbacks that we did experience over the last 6 months. That included the sale leaseback, the convertible debt and paying down old debt to make sure there was nothing major due in the near term. We continue to operate and focus on building out our strategic plans and growing our company on the pathway to success. And third, the pipeline. We really did advance the pipeline forward by [purchase] at quorum, the feedback we're getting...
